Basic information Cyclooxygenase -2 (COX-2) inhibitors Pharmacological effects Pharmacokinetics Drug Interactions Indications Safety Safety Related Supplier
ChemicalBook >  Product Catalog >  API >  Antipyretic analgesics >  Antigout Drugs >  Etoricoxib

Etoricoxib

Etoricoxib is a kind of highly selective cyclooxygenase-2 (COX-2) inhibitors developed by the Merck company with the chemical name being 5-chloro-6'-methyl -3-4-(methanesulfonamide) phenyl]-2, 3'-bipyridine. Etoricoxib has a unique chemical structure that is methylsulfonyl group. The introduction of this group can not only increase the selectivity for COX-2 drugs, but also does not produce sulfa drugs and cross-allergic reactions.

Basic information Cyclooxygenase -2 (COX-2) inhibitors Pharmacological effects Pharmacokinetics Drug Interactions Indications Safety Safety Related Supplier
Etoricoxib Basic information
Etoricoxib Chemical Properties
  • Melting point:134-135°C
  • Boiling point:510.0±50.0 °C(Predicted)
  • Density 1.298±0.06 g/cm3(Predicted)
  • storage temp. -20°C Freezer
  • pka4.5(at 25℃)
  • form neat
  • BRN 8073797
  • InChIKeyMNJVRJDLRVPLFE-UHFFFAOYSA-N
  • CAS DataBase Reference202409-33-4(CAS DataBase Reference)
Safety Information
  • Hazard Codes T
  • Risk Statements 22-24
  • Safety Statements 36/37-45
  • RIDADR UN 2811 6.1 / PGII
  • WGK Germany 3
Etoricoxib Usage And Synthesis
  • Cyclooxygenase -2 (COX-2) inhibitorsEtoricoxib is a kind of highly selective cyclooxygenase-2 (COX-2) inhibitors developed by the Merck company with the chemical name being 5-chloro-6'-methyl-3-4-(methanesulfonamide) phenyl]-2, 3'-bipyridine. Etoricoxib has a unique chemical structure that is methylsulfonyl group. The introduction of this group can not only increase the selectivity for COX-2 drugs, but also does not produce sulfa drugs and cross-allergic reactions. Etoricoxib was first approved for entering into market in 2002 in the UK, followed by the marketing countries and regions including the European Union, Asia, Australia and Latin America. Until the end of 2013, it has been approved for marketing in 97 countries for being widely used in treatment of osteoarthritis (OA), rheumatoid arthritis, ankylosing spondylitis, chronic low back pain, acute gouty arthritis, primary dysmenorrhea and postoperative pain, and other diseases. Etoricoxib has also entered into market in Taiwan and Hong Kong of China. It had entered into market in Chinese mainland in 2008 with the approved indications being acute gouty arthritis and OA and another indication being primary dysmenorrhea in the second half year of 2014.
  • Pharmacological effectsEtoricoxib is a non-steroidal anti-inflammatory drug with anti-inflammatory, analgesic and antipyretic effects in animal models. It is a kind of orally active, selective cyclooxygenase-2 inhibitor within the clinical dose range or higher doses. It has already confirmed of two subtypes of cyclooxygenase: cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2). COX-1 is involved in the prostaglandin mediated normal physiologic functions such as gastric cytoprotection and platelet aggregation. Non-selective non-steroidal anti-inflammatory drugs inhibit the generation of COX-1, and thus can cause gastric mucosal injury and decreased platelet aggregation. COX-2 is mainly involved in the production of prostaglandins, and prostaglandins can cause pain, inflammation and fever. Etoricoxib is a kind of selective COX-2 inhibitors which can reduce these symptoms and signs as well as reduce gastrointestinal side effects without affecting platelet function.
    The above information is edited by the chemicalbook of Dai Xiongfeng.
  • PharmacokineticsAbsorption: it has excellent oral absorption with the mean oral bioavailability being close to 100%. For adult, it can be subject to oral administration of 120mg upon empty stomach for once daily until it reaches steady state. Its plasma concentration reaches peak in about 1 hour after drug administration. This pharmacokinetic of this product exhibits linear correlation within clinical dose range.
    Distribution: in the concentration range 0.05-5mcg/ml; 92% binds to human plasma protein. In the human body, volume of distribution at steady state is approximately 120 liters. It can penetrate the placenta of rats and rabbits as well as the blood-brain barrier in rats.
    Metabolism: Metabolic is complete with the proto-drug content in the urine being less than 1%. The main metabolic pathway is through the catalysis through the enzyme cytochrome P450 (CYP), forming a six-carboxylic acid derivative.
    Clearance: In healthy individuals, intravenous administration of radio-labeled Etoricoxib; 70% of the radioactivity could be detected in the urine, 20% of the radioactivity could be detected in the feces while most of them being in the form of the presence of metabolites and only less than 2% of the prototype drug is excreted.
  • Drug InteractionsWarfarin: long-term usage of warfarin therapy in patients with stable efficacy. Daily application of this drug should be 120mg with the prothrombin time being approximately 13% higher than the international normalized ratio (INR).
    Rifampicin: Rifampicin is a strong inducer of hepatic metabolism. The combination of this product with rifampicin allows the plasma area under the curve (AUC) to be reduced by 65%. Therefore when this product is combined with rifampin, we should take into account their interaction.
    Methotrexate: When using this product at a dose greater than 90mg/day as well as being in combination with methotrexate, you should consider monitoring the toxicity associated with methotrexate.
    Diuretics, angiotensin-converting enzyme (ACE) inhibitors and angiotensin II antagonists (AIIAs): Non-steroidal anti-inflammatory drugs, including selective cyclooxygenase-2 inhibitors can reduce the antihypertensive effect of the diuretics, angiotensin converting inhibitors and angiotensin II antagonists.
    Lithium salt: non-selective non-steroidal anti-inflammatory drugs and cyclooxygenase-2 selective inhibitors may increase plasma levels of lithium salts.
    Aspirin: It can be used simultaneously with a lose-dose aspirin for the prevention of cardiovascular events. However, upon being in combination with low-dose aspirin, the incidence of gastrointestinal ulcers or other complication rate is higher than in the case of single usage of this product.
    Oral contraceptives: upon selecting suitable oral contraceptives for being used in combination with this product, we need to take into account of the increase of the EE concentration. The increase of the EE concentration will increase the incidence of the related adverse events of oral contraceptives (such as the risk of venous thromboembolism for women).
    Other: Antacids and ketoconazole (CYP3A4 strong inhibitors) do not produce clinically significant impact on the pharmacokinetics of this product.
  • Indications1. the treatment of OA: the good has a comparable effect as celecoxib, ibuprofen with similar efficacy with large doses of diclofenac and naproxen.
    2. acute gouty arthritis: This product is 120 mg/d and can quickly and effectively relieve pain, and has a similar efficacy as the gold standard drug indomethacin in the treatment of gouty arthritis with a better tolerance and a lower incidence of drug-related adverse events than indomethacin.
    3. ankylosing spondylitis: etoricoxib has a similar efficacy as naproxen taken twice per day; etoricoxib has a better effect in treating secondary end-point aspects such as alleviating night pain, inflammation, functionality and flexibility.
    4. rheumatoid arthritis: large-scale, controlled clinical trial results showed that etoricoxib taken once daily has a better efficacy compared to naproxen taken twice daily with a better tolerance in patients.
    5. osteoarthritis: This product (once/day) has a comparable efficacy as celecoxib (once/day), and ibuprofen (3 times/day); and it (once/day) has a similar efficacy with high-dose diclofenac (3 times/day) and naproxen (3 times/day).
    6. postoperative dental pain: compared with acetaminophen/codeine and oxycodone/ p-acetaminophen, taking etoricoxib once daily can yield a better efficacy in alleviating the pain feeling of patients.
    7. chronic low back pain: compare this product with Placebo on the treatment efficacy of chronic low back pain in 12 weeks has demonstrated that the clinical efficacy of this product was significantly superior to placebo drug with being effective in the treatment for only one week while the effect is very significant in four weeks and the sustained effect being able to reach over three months.
    8. for controlling late pain of postoperative thyroid: when thyroid operation patients orally take etoricoxib at 1 h before operation can reduce the oral administrated dose of oxycodone acetaminophen at 6~12 h after surgery in patients.
  • SafetyCompared with diclofenac, the incidence of this product in inducting thrombotic cardiovascular events has no significant difference while the cumulative incidence of clinically diagnosed gastrointestinal perforation, ulcers, bleeding in etoricoxib group was significantly lower than the diclofenac group. The incidence of gastrointestinal adverse events is decreased by 50% compared with the diclofenac sodium. Etoricoxib has a low gastrointestinal reaction. During the treatment, the gastrointestinal symptoms (nausea, vomiting, abdominal pain or discomfort, diarrhea), chest and ankle edema and other adverse events for etoricoxib is similar to other selective COX-2 inhibitors. It is contraindicated in patients with ischemic heart disease and stroke. For patients with risk factors such as heart disease, they should use with caution.
  • DescriptionEtoricoxib is a COX-2 inhibitor developed as a follow-up of rofecoxib for the treatment of osteoarthritis, rheumatoid arthritis, dysmenorrhoea, gout, ankylosing spondylitis and pain. Several processes describe the preparation of etoricoxib in 4 or 5 steps from 6- methylnicotinate. The key step is the novel pyridine construction using annulation of a ketosutfone with a vinamidinium synthon. In human whole blood, in vitro, the IC50 value obtained for inhibition of COX-2 is 1 .I μM as compared to 116 μM obtained for inhibition of COX-1. Thus, etoricoxib is the most selective COX-2 inhibitor to date, with a COX-IKOX- 2 ratio of IC50 values of 106 for etoricoxib as compared to 35, 30, 7.6 for rofecoxib, valdecoxib and celecoxib, respectively. Its in vivo potency is generally comparable to that of rofecoxib in animal models against inflammation (carrageenan-induced paw edema), pyrexia (LPS-induced pyresis), pain (carrageenan-induced hyperalgesia) and arthritis (adjuvant-induced arthritis). Etoricoxib is well tolerated with dose-proportional pharmacokinetics. It has no effect on bleeding time or platelet ag regation. The gastrointestinal tolerability of etoricoxib is excellent as demonstrated by [51Cr] models of excretion in rats and squirrel monkeys. Moreover, etoricoxib, unlike naproxen is not associated with significant inhibition of gastric mucosal PGE2 synthesis compared to placebo. Etoricoxib is highly absorbed, has a tmax of 1.5 h and a half-life time of approximately 15-22h. Five metabolites, weak inhibitors of COX-1 and COX-2 have been identified after renal excretion. Finally, although multiple CYP enzymes are involved in the metabolism of etoricoxib (CYP3A4 being the major contributor), etoricoxib is not a potent CYP3A4 inhibitor or inducer. In patients undergoing molar extraction, etoricoxib showed similar efficacy to naproxen sodium with a longer duration of analgesia than acetaminophen/codeine (approximately >24 h, 22 h and 5.2 h, respectively) and a better total pain relief score over 8 h. Similar efficacy of etoricoxib and naproxen was also seen in patients suffering of osteoarthritis. In the treatment of rheumatoid arthritis and ankylosing spondylitis, etoricoxib demonstrated significantly superior efficacy compared to naproxen and placebo. Etoricoxib did not affect the pharmacokinetics of prednisolone (i.v. or p.0.) and its co-administration with antacids showed insignificant effects on the maximal concentration and its absorption. .
  • Chemical PropertiesOff-White Powder
  • OriginatorMerck & Co (USA)
  • UsesA specific inhibitor of COX-2 .
  • Usesanti-inflammatory, analgesic;cyclooxygenase inhibitor
  • UsesFor the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute pain and gout.
  • UsesLabeled Etoricoxib, intended for use as an internal standard for the quantification of Etoricoxib by GC- or LC-mass spectrometry.
  • UsesEtoricoxib is a dipyridinyl compound that demonstrates high in vitro and ex vivo selectivity for COX-2 over COX-1 in several assays, e.g., in the production of PGE2 by CHO cells expressing either COX-2 (IC50 = 79 nM) or COX-1 (IC50 > 50 μM). Oral etoricoxib is well absorbed and metabolized extensively via oxidation, with metabolites excreted largely in the urine.[Cayman Chemical]
  • DefinitionChEBI: A member of the class of bipyridines that is 2,3'-bipyridine which is substituted at the 3, 5, and 6' positions by 4-(methylsulfonyl)phenyl, chlorine, and methyl groups, respectively.
  • brand nameArcoxia
  • PharmacokineticsEtoricoxib is rapidly absorbed, with an oral bioavailability of 80 to 100%, and reaches maximum plasma concentrations in 1 to 2 hours after dosing. Food decreases the rate of absorption but has no effect on the extent of absorption. It exhibits a long elimination half-life of approximately 22 hours, demonstrating linear plasma pharmacokinetics with no accumulation during multiple dosing.
  • Clinical UseEtoricoxib is a selective COX-2 inhibitor being developed for postsurgical treatment of dental pain (120 mg) and osteoarthritis. It has a methylsulfonyl group common to the other coxib inhibitors.
  • Metabolism Etoricoxib is metabolized involving oxidation of its 6′-methyl group primarily by CYP3A4 but is not an inhibitor of CYP3A4. Other metabolites include 1′-N-oxide and glucuronides. Etoricoxib is primarily excreted as metabolites into the urine.
Etoricoxib(202409-33-4)Related Product Information
EtoricoxibSupplierMore
  • Company Name:Suzhou Huihe Pharmaceutical Co. Ltd. Gold
  • Tel:86-0512-88819360/88985990
  • Email:asynderm@163.com
  • Products Intro:Product Name:Etoricoxib
    CAS:202409-33-4
    Purity:99.9% Package:1kg,5kg,10kg
  •  
  • Company Name:Chengdu Climb Pharmaceutical Technology Co., Ltd. Gold
  • Tel:13540107218 028-87608726
  • Email:sales@cdclimb.com
  • Products Intro:Product Name:Etoricoxib
    CAS:202409-33-4
    Purity:99%
  •  
  • Company Name:Shaanxi Jiandu Pharmaceutical Chemical Co. Ltd. Gold
  • Tel:13379181735 029-89586682-
  • Email:support@dideu.com;support@dideu.com
  • Products Intro:Product Name:Etoricoxib
    CAS:202409-33-4
    Purity:99% ,EP 9.0/BP 2015/USP 39 Package:25KG/2250
  •  
  • Company Name:Guangzhou Tonghui Pharmaceutical Co., Ltd. Gold
  • Tel:18026299762 020-66392416
  • Email:3004254637@qq.com
  • Products Intro:Product Name:Etoricoxib
    CAS:202409-33-4
    Purity:99.70% Package:25KG
  •  
  • Company Name:Chengdu Beiyu Pharmaceutical Technology Co., Ltd. Gold
  • Tel:028-85051141
  • Email:cao_qin@foxmail.com
  • Products Intro:Product Name:Etoricoxib
    CAS:202409-33-4
    Purity:99% Package:100g;1kg;5kg Remarks:ADVANCED INTERMEDIATES
  •